ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 98 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,126,953 | -36.3% | 443,067 | -0.3% | 0.00% | – |
| Q2 2023 | $3,336,677 | +75.3% | 444,298 | +5.5% | 0.00% | – |
| Q1 2023 | $1,903,118 | +40862.5% | 421,044 | +2.1% | 0.00% | -100.0% |
| Q4 2022 | $4,646 | -99.9% | 412,309 | +4.8% | 0.00% | 0.0% |
| Q3 2022 | $3,764,000 | +22.4% | 393,321 | +3.5% | 0.00% | – |
| Q2 2022 | $3,075,000 | -43.2% | 380,200 | +18.7% | 0.00% | -100.0% |
| Q1 2022 | $5,413,000 | -25.9% | 320,341 | -5.7% | 0.00% | 0.0% |
| Q4 2021 | $7,303,000 | -72.6% | 339,846 | -5.7% | 0.00% | -75.0% |
| Q3 2021 | $26,615,000 | +74.9% | 360,346 | +29.5% | 0.00% | +100.0% |
| Q2 2021 | $15,216,000 | -24.1% | 278,277 | +2.3% | 0.00% | -33.3% |
| Q1 2021 | $20,058,000 | +28.7% | 272,017 | +50.4% | 0.00% | 0.0% |
| Q4 2020 | $15,590,000 | +167.2% | 180,868 | +17.0% | 0.00% | +200.0% |
| Q3 2020 | $5,835,000 | – | 154,629 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |